TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

TOT BIOPHARM International Company Limited

Equities

1875

HK0000545266

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
1.55 ^HKD	+1.97%		-5.49%	-21.32%

Mar. 15	TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TOT Biopharm's Loss Narrows in January-September Period	MT

TOT BIOPHARM International Company Limited Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021

May 10, 2021 at 06:32 am EDT

TOT BIOPHARM International Company Limited reported unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the quarter, revenue was RMB 14,584,000 against RMB 7,300,000 a year ago. Net loss was RMB 42,715,000 against RMB 58,367,000 a year ago.

Latest news about TOT BIOPHARM International Company Limited

TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
TOT Biopharm's Loss Narrows in January-September Period	Nov. 10	MT
TOT Biopharm's Loss Narrows in H1	23-08-14	MT
TOT BIOPHARM International Company Limited Announces Directorate and Committee Changes	23-08-11	CI
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
TOT BIOPHARM's Q1 Loss Widens Despite Higher Revenue	23-05-12	MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
TOT Biopharm Terminates Phase 3 Trial of Breast Cancer Drug; Shares Fall 5%	23-03-20	MT
TOT BIOPHARM International Company Limited Announces Termination of Phase III Clinical Trial Study and Development of Taa013	23-03-17	CI
TOT BIOPHARM’s Production Base for Antibody Drug Receives Good Manufacturing Report from Europe	22-10-26	MT
TOT BIOPHARM International Company Limited Announces Change of Address of Registered Office	22-08-15	CI
TOT Biopharm International Logs Reduction in H1 Net Loss; Shares Climb 3%	22-08-15	MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
TOT BIOPHARM International Company Limited announced that it expects to receive HKD 110 million in funding from Center Laboratories, Inc.	22-05-30	CI
TOT Biopharm Narrows Loss on Lower Selling, R&D Expenses in 2021	22-03-24	MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
TOT BIOPHARM International Company Limited Announces Change of Directors and Change of Composition of Board Committees	22-03-13	CI
China Approves New Indications for TOT Biopharm's Cancer Drug	22-03-10	MT
TOT BIOPHARM International Company Limited Announces Change of Joint Company Secretary and Finance Personnel	22-01-31	CI
TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Overseas	22-01-12	MT
TOT Biopharm Arm Engages MCC Unit to Construct Global R&D Center in Chinese Province	22-01-03	MT
TOT Biopharm Sells 1 Million Shares in Lumosa Therapeutics to Center Laboratories	21-12-08	MT
TOT BIOPHARM International Company Limited Announces NMPA Granted Marketing Approval for Pusintin in China	21-12-01	CI
TOT Biopharm's Lung Cance Drug Bags Marketing Approval in China; Shares Rally 5%	21-12-01	MT
TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical	21-11-23	MT

Chart TOT BIOPHARM International Company Limited

Duration

Period

Chart TOT BIOPHARM International Company Limited

More charts

Company Profile

TOT BIOPHARM International Company Limited is a company mainly engaged in the development and commercialization of oncology drugs and therapies. The Company has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.405 CNY

Average target price

3.486 CNY

Spread / Average Target

+148.12%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED	-21.32%	150M
VERTEX PHARMACEUTICALS INCORPORATED	-2.74%	102B
REGENERON PHARMACEUTICALS, INC.	+2.27%	96.07B
ARGENX SE	-1.75%	21.66B
BIONTECH SE	-17.53%	20.77B
GENMAB A/S	-7.10%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-28.23%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.15%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.54%	10.94B

Bio Therapeutic Drugs